Short name: Gd-DTPA mesoporphyrin, generic name: gadophrin, central moiety: Gd2+
Gd-DTPA mesoporphyrin is a substance under development (Bayer Schering Pharma AG) as a positive enhancing myocardium- and necrosis- targeted MRI contrast agent.

See also Metalloporphyrins and Necrosis Avid Contrast Agent.

Short name: Gd-DTPA-PEG, generic name: Gd-DTPA-PEG polymers, chemical compound: Gadolinium DTPA polyethylene glycol, central moiety: Gd2+, relaxivity: r1=6.0, B0=1.0 T
A substance under development (preclin.) as an intravascular MRI contrast agent for MR angiography and capillary permeability detection.

Short name: PLLGd-DTPA, generic name: (Gd-DTPA)n-polylysine, chemical compound: Gd-DTPA poly(L-lysine-Gd-diethylenetriamine-N,N,N',N'',N''-pentaacetic acid), central moiety: Gd2+, relaxivity: r1=13.1, B0=0.23T
A polymeric MRI contrast agent under development (preclin., Bayer Schering Pharma AG, Berlin, Germany) with advantages in both MRA and in the differential diagnosis of tumors, particularly in perfusion studies of the myocardium and potential in MR lung perfusion. Dozens of the relatively small molecule Gd-DTPA is bound covalently to polylysine, a large molecular weight backbone. The stable, highly water-soluble agent does not diffuse through the endothelium of the vascular system; it is subject to renal elimination.

Short name: Gd-TPPS, central moiety: Gd2+
Gd-tetraphenyl-porphyrin sulfonate is a MRI contrast agent under development (preclin.) with tumor selective uptake for tumor detection and control.

See also Metalloporphyrins.

Short name: GdDOTA-4AmP, central moiety: Gd
A pH-sensitive gadolinium-based contrast agent under development to image tissue pH in vivo by MRI.